Camlin Fine Sciences (532834) Panoramica del titolo
Camlin Fine Sciences Limited, insieme alle sue consociate, si occupa di ricerca, sviluppo, produzione e commercializzazione di prodotti chimici speciali, ingredienti e miscele di additivi in India e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
532834 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Camlin Fine Sciences Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹121.35 |
| Massimo di 52 settimane | ₹334.70 |
| Minimo di 52 settimane | ₹96.30 |
| Beta | 0.72 |
| Variazione di 1 mese | 16.90% |
| Variazione a 3 mesi | -14.84% |
| Variazione di 1 anno | -37.06% |
| Variazione a 3 anni | -29.81% |
| Variazione a 5 anni | -36.11% |
| Variazione dall'IPO | 1,327.65% |
Notizie e aggiornamenti recenti
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Recent updates
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Rendimenti per gli azionisti
| 532834 | IN Chemicals | IN Mercato | |
|---|---|---|---|
| 7D | 2.1% | 2.1% | 0.7% |
| 1Y | -37.1% | -2.0% | -0.3% |
Ritorno vs Industria: 532834 ha avuto una performance inferiore rispetto al Indian Chemicals che ha registrato un rendimento -2 % nell'ultimo anno.
Rendimento vs Mercato: 532834 ha avuto una performance inferiore al mercato Indian che ha registrato un rendimento -0.3 % nell'ultimo anno.
Volatilità dei prezzi
| 532834 volatility | |
|---|---|
| 532834 Average Weekly Movement | 8.5% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Prezzo delle azioni stabile: 532834 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di 532834 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1931 | 661 | Ashish Dandekar | www.camlinfs.com |
Camlin Fine Sciences Limited, insieme alle sue consociate, è impegnata nella ricerca, nello sviluppo, nella produzione e nella commercializzazione di prodotti chimici speciali, ingredienti e miscele di additivi in India e a livello internazionale. L'azienda offre soluzioni per la conservabilità, che comprendono antiossidanti come l'idrossitoluene butilato e il palmitato di ascorbile, emulsionanti, inibitori di muffa, agenti antibatterici, leganti di tossine, leganti di pellet, disinfettanti, energizzanti, conservanti, addensanti e promotori della crescita, nonché antiossidanti a base vegetale, come i tocoferoli misti, l'estratto di tè verde e l'estratto di rosmarino, utilizzati per migliorare la conservabilità con i marchi Xtendra e NaSure. L'azienda fornisce anche ingredienti aromatici, tra cui vanillina ed etilvanillina, prodotti per la salute e il benessere e prodotti chimici per le prestazioni, come idrochinone e catecolo.
Camlin Fine Sciences Limited Riepilogo dei fondamenti
| 532834 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹23.31b |
| Utili (TTM) | -₹140.89m |
| Ricavi(TTM) | ₹17.78b |
532834 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 532834 Conto economico (TTM) | |
|---|---|
| Ricavi | ₹17.78b |
| Costo del fatturato | ₹9.86b |
| Profitto lordo | ₹7.92b |
| Altre spese | ₹8.06b |
| Utili | -₹140.89m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 26, 2026
| Utile per azione (EPS) | -0.73 |
| Margine lordo | 44.54% |
| Margine di profitto netto | -0.79% |
| Rapporto debito/patrimonio netto | 78.1% |
Come si è comportato 532834 nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 02:26 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Camlin Fine Sciences Limited è coperta da 9 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |